Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO) — CALLISTO

Congenital Muscular Dystrophy Clinical Trial

Official title:
Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)

Status Completed

Clinical Trial Summary

The purpose of the study is to establish the pharmacokinetic profile of omigapil in paediatric and adolescent patients with CMD and to evaluate the safety and tolerability of omigapil. Funding source - FDA OOPD

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01805024
Study type	Interventional
Source	Santhera Pharmaceuticals
Contact
Status	Completed
Phase	Phase 1
Start date	December 2014
Completion date	January 29, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04001595` - Global FKRP Registry
Recruiting	`NCT05102916` - Swiss Registry for Neuromuscular Disorders
Recruiting	`NCT05982119` - Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study	N/A
Completed	`NCT01422200` - Flu Vaccine Study in Neuromuscular Patients 2011	Phase 4
Completed	`NCT01836627` - A Study to Test Lung Stretch Therapy (Hyperinsufflation) in Children With Collagen VI Muscular Dystrophy	N/A